Short answer
UNITED THERAPEUTICS Corp (UTHR) filed an 8-K current report with the SEC on July 23, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Board expanded to 13 members with Victor Dzau, M.D. appointed as director on July 22, 2026.
UNITED THERAPEUTICS Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded to 13 members with Victor Dzau, M.D. appointed as director on July 22, 2026
- No initial committee assignment, limiting immediate committee-level influence
- Equity awards total 730 restricted stock units and 2,300 stock options under the 2026 Stock Incentive Plan
- Appointment includes standard director compensation and indemnification arrangements
- No reportable related-party transactions exceeding $120,000 involving Dr. Dzau
Item 7.01 · Regulation FD Disclosure
- Press release announces Dr. Dzau’s appointment
- Appointment represents a leadership or governance change requiring investor review of Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Victor Dzau appointed to United Therapeutics’ board on July 22, 2026
- High-profile healthcare leadership adds expertise in biomedical research, healthcare systems, and organ-transplant innovation
- Appointment supports the company’s board refreshment and organ-alternatives strategy
- No compensation, committee assignment, or ownership terms disclosed in the announcement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other UNITED THERAPEUTICS Corp 8-K filings
Get the next UTHR 8-K as it lands
Follow UTHR for push alerts, or ask the research agent what this filing means.